missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Novus Biologicals™ CD3 Antibody (otelixizumab) - Humanized, Novus Biologicals™
Human Monoclonal Antibody
Brand: Novus Biologicals™ NBP3-28865-100ug
This item is not returnable.
View return policy
Description
CD3 Monoclonal antibody specifically detects CD3 in Human samples. It is validated for Flow Cytometry,ELISA,Functional Assay
Specifications
| CD3 | |
| Monoclonal | |
| Unconjugated | |
| P07766 | |
| Human | |
| Protein A purified | |
| RUO | |
| Primary | |
| Reconstitute with sterile, distilled water to a final concentration of 1 mg/mL. Gently shake to solubilize completely. Do not vortex. | |
| Store at -20°C in powder form. Store at -80°C once reconstituted. | |
| IgG1 |
| Flow Cytometry, ELISA, Functional Assay | |
| otelixizumab | |
| Lyophilized from 25mM histidine, 8% sucrose, 0.01% Tween80 (pH6.2) | |
| CD_antigen: CD3e, CD3 antigen, delta subunit, CD3d antigen, CD3d antigen, delta polypeptide (TiT3 complex), CD3d molecule, delta (CD3-TCR complex), CD3-DELTA, CD3e, CD3e antigen, CD3e antigen, epsilon polypeptide (TiT3 complex), CD3e molecule, epsilon (CD3-TCR complex), CD3-epsilon, CD3G, CD3g antigen, CD3g antigen, gamma polypeptide (TiT3 complex), CD3g molecule, epsilon (CD3-TCR complex), CD3g molecule, gamma (CD3-TCR complex), CD3-GAMMA, FLJ17620, FLJ17664, FLJ18683, FLJ79544, FLJ94613, IMD18, MGC138597, T3DOKT3, delta chain, T3E, T-cell antigen receptor complex, epsilon subunit of T3, T-cell receptor T3 delta chain, T-cell surface antigen T3/Leu-4 epsilon chain, T-cell surface glycoprotein CD3 delta chain, T-cell surface glycoprotein CD3 epsilon chain, TCRE | |
| CD3 | |
| 100 μg | |
| Adaptive Immunity, Apoptosis, Autoimmune Diseases, Diabetes Research, Immunology, Inflammation, Innate Immunity, Signal Transduction, Stem Cells | |
| 916 | |
| Human | |
| Purified |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction